Old Line Capital Partners has made a significant investment in KaloCyte, Inc., to extend the research and development of break-through human blood substitute ErythroMer.
Click here to read the news release issued by Old Line Capital.
KaloCyte in the News: Old Line Capital Invests in KaloCyte
